Certified by Founder
Lodge
Kinaset Therapeutics
start up
- 13/01/2026
- Series B
- $103,000,000
At Kinaset Therapeutics, we intend to develop novel respiratory therapeutics that can positively impact people affected by intractable diseases. Our novel lead asset and experienced team combine a potentially best in class approach to treating severe asthma
- Industry Pharmaceutical Manufacturing
- Website https://www.kinasettherapeutics.com/
- LinkedIn https://www.linkedin.com/company/kinaset-tx/
Mecka | $60,000,000 | (Jun 3, 2026)
Novellia | $18,000,000 | (Jun 3, 2026)
Plot | $10,000,000 | (Jun 3, 2026)
KOSMOS | $5,000,000 | (Jun 3, 2026)
Phosio Corporation | $4,000,000 | (Jun 3, 2026)
StratusGrid | $3,000,000 | (Jun 3, 2026)
Subtle Medical | $33,000,000 | (Jun 3, 2026)
Tavo Biotherapeutics | $17,000,000 | (Jun 3, 2026)
Gigaton | $26,000,000 | (Jun 3, 2026)
Westmag | $11,000,000 | (Jun 3, 2026)
Inherent | $50,000,000 | (Jun 2, 2026)